Mapp Biopharmaceutical Inc
United States of America
Kevin Whaley has worked for the last 30 years on the development of multipurpose prevention technologies (MPTs), i.e. products that simultaneously prevent sexually transmitted diseases and unwanted pregnancy. He co-founded Mapp to develop antibody-based MPTs, therapeutics and mucosal vaccines that are appropriate for large, cost-sensitive, global health markets.